NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, an...

NSC antagonists are disclosed as useful in the treatment of dementia in delaying the onset of dementia and in the prevention of dementia. Dementia so treated may be for example Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone a) in combination with other drugs used for treating dementia b) in combination with drugs that stabilize or increase blood plasma glucose levels or with both a) and b). Pharmaceutical compositions dosage forms and methods...

A combination comprising 2 to 8 mg of 5-[4-[2-(N-methyl-N- (2-pyridyl)amino)-ethoxy]benzyl]thiazolidine-24-dione (rosiglitazone) or a tautomeric form thereof or a pharmaceutically acceptable salt or solvate thereof; and sub maximal amount of sulphonylurea selected from glibenclamide glipizide gliclazide tolazamide tolbutamide acetohexamide carbutamide chlorpropamide glibornuride gliquidone glisentide glisolamide glisoxepide glyclopyamide and glycylamide. Disclosed is also a medical use of the co...

PURPOSE: A combination kit containing pinitol and a drug for preventing or treating diabetes is provided to reduce side effects and to quickly treat diabetes. CONSTITUTION: A combination kit of a component for preventing or treating diabetes contains pinitol as a first ingredient and a drug of biguanide meglitinide or sulfonylurea as a second ingredient. The biguanide is metformin. The meglitinide is repaplinide or nateglinide. The sulfonylurea is carbutamide acetohexamide chlorpropamide tolbuta...

595024 Disclosed herein is a compound which is NN-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbomoyl-4-yloxy)pyrimidine-2-carboxamide a pharmaceutical composition comprising it and a pharmaceutical composition further comprising an anti-obesity agent and an anti-diabetic agent. Wherein said anti-obesity agent is selected from the group consisting of dirlotapide mitratapide implitapide lorcaserin cetilistat PYY3-36 naltrexone oleoyl-estrone obinepitide pramlintide tesofensine leptin liraglut...

A composition comprising a novel Ca2-activated [ATP]-sensitive nonspecific cation (NCca ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion which causes severe cell depolarization followed by cell swelling- The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulf...

A composition comprising a novel Ca2+-activated [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion which causes severe cell depolarization followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by su...

A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited b...